Goldman Sachs: Maintain a shareholding rating for Prime Medicine (PRME.US), adjusting its target price from $16.00 to $15.00.
小摩：维持Prime Medicine(PRME.US)评级，由增持调整至增持评级, 目标价由16.00美元调整至15.00美元。
Komo: Maintaining the Prime Medicine (PRME.US) rating, adjusted from an increase in holdings to an increase in holdings rating, and the target price was adjusted from $16.00 to $15.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.